SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Higuchi Ichiyō Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientHiguchi Ichiyō
Date of birth1872-05-02
IdentifiersMRN HR-NI029-SYN-TD; SSN (made up) 000-29-5108
Document date2026-11-01
AuthorAiko Lindgren-Tanaka, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient visit for seven weeks of cough, fevers, night sweats and weight loss: chest X-ray, sputum specimens, blood tests, airborne precautions, and a report of suspected tuberculosis to the public health center. Concerns: She has coughed for weeks, sweats at night and has lost weight, and fears it is tuberculosis; She supports her household by writing and cannot afford to stop working or to pay for many tests; She is afraid of passing the illness to the people she lives with and of what neighbors and editors will think. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Isoniazid 100 mg tablets, two tablets (200 mg) daily200 mg once daily, observed by video each day through the public health center's directly observed treatment program, for 26 weeksOral route1896-04-17 to 1896-10-15completedS
Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily450 mg once daily on an empty stomach, observed by video each day through the public health center's directly observed treatment program, for 26 weeksOral route1896-04-17 to 1896-10-15completedS
Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily1000 mg once daily, observed by video each day through the public health center's directly observed treatment program, for the eight-week intensive phaseOral route1896-04-17 to 1896-06-11completedS
Ethambutol 100 mg tablets, six tablets (600 mg) daily600 mg once daily, observed by video each day through the public health center's directly observed treatment program, until susceptibility results returnOral route1896-04-17 to 1896-05-22stoppedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route1896-04-17 to 1896-10-15completedS
Nitrofurantoin monohydrate/macrocrystals 100 mg oral capsule, one capsule twice daily with food for five daysOne capsule twice daily with food for five daysOral route1896-07-20 to 1896-07-24completedS

Procedures

ProcedureDatesStatusEvidence
Chest X-ray, two views: patchy opacities in the apical and posterior segments of the right upper lobe with small nodules; no cavity, effusion or hilar enlargement1896-04-14 to 1896-04-14completedS
Chest X-ray, two views, at the end of treatment: right upper lobe opacities cleared, leaving a few linear scars; kept as the baseline for any future comparison1896-10-20 to 1896-10-20completedS
Cervical cytology (Papanicolaou test), first screening1896-08-24 to 1896-08-24completedS
Advance care planning conversation, about 16 minutes1896-08-24 to 1896-08-24completedS

Immunizations

DateVaccineStatusEvidence
1896-08-24Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)completedS
1896-08-24Hepatitis B vaccine (HepB-CpG), dose 1 of 2completedS
1896-08-24Human papillomavirus 9-valent vaccine, dose 1 of 3completedS
1896-10-20Hepatitis B vaccine (HepB-CpG), dose 2 of 2completedS
1896-10-20Human papillomavirus 9-valent vaccine, dose 2 of 3completedS
1896-10-20Influenza vaccine, inactivated, trivalent, preservative-freecompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

No historical medical events are recorded.

Family History

RelativeConditionAge at deathEvidence
fatherDied of illness in 1889; cause not recorded in the cited sourceD (CLM-0004)

Health Concerns

ConcernStatusEvidence
She has coughed for weeks, sweats at night and has lost weight, and fears it is tuberculosisactiveS
She supports her household by writing and cannot afford to stop working or to pay for many testsactiveS
She is afraid of passing the illness to the people she lives with and of what neighbors and editors will thinkactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 13.2 on 1896-10-20; Leukocytes [#/volume] in Blood by Automated count 8.6 on 1896-04-14; Platelets [#/volume] in Blood by Automated count 452 on 1896-04-14; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 18 on 1896-10-20; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 on 1896-10-20; Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 on 1896-06-12; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 74 on 1896-04-14; Albumin [Mass/volume] in Serum or Plasma 4.2 on 1896-10-20; Creatinine [Mass/volume] in Serum or Plasma 0.56 on 1896-04-14; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1891)/1.73 sq M 131 on 1896-04-14; Glucose [Mass/volume] in Serum or Plasma 82 on 1896-04-14; Hemoglobin A1c/Hemoglobin.total in Blood 5.1 on 1896-04-14; Visual acuity uncorrected Right eye by ETDRS eye chart 85 on 1896-06-12; Visual acuity uncorrected Left eye by ETDRS eye chart 85 on 1896-06-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 1896-10-20; Total score [AUDIT-C] 0 on 1896-08-24; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 1896-08-24; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 4 on 1896-08-24 [S]

Strengths and supports: Supports and strengths she names: her writing, her readers and editors, and the poetry she studied when young [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Cough for about seven weeks with evening fevers, night sweats, poor appetite and weight loss of about 4 kg (about 10 percent) in a woman of 23; chest X-ray with patchy right upper lobe opacities and no cavity; suspected pulmonary tuberculosis; airborne precautions and three sputum specimens for acid-fast smear, nucleic acid amplification and cultureresolvedconfirmed R05.3S — Synthetic presenting problem at intake, superseded by the diagnosis at the second visit; its timing echoes her documented decline from early 1896 (D).
Pulmonary tuberculosis of the right upper lobe, sputum smear-negative, confirmed by Xpert MTB/RIF Ultra (Mycobacterium tuberculosis detected, low; rifampin resistance not detected)resolvedconfirmed A15.0S — Synthetic modern coding of her documented tuberculosis; all bacteriology and imaging are synthetic.
Moderate protein-calorie malnutrition: BMI 17.6, about 10 percent weight loss in two months, and albumin 3.3 g/dLresolvedconfirmed E44.0S — Synthetic nutrition diagnosis at intake, anchored to her documented poverty.
Low and irregular income from writing, with a household to support; costs of care are a barrieractiveconfirmed Z59.6S — Synthetic social need anchored to her documented poverty and household responsibilities.
Acute uncomplicated cystitis, treated with nitrofurantoin rather than a fluoroquinolone during tuberculosis treatment; resolvedresolvedconfirmed N30.00S — Synthetic intercurrent illness; not a historical claim.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1896-04-14Hemoglobin [Mass/volume] in Blood11.4g/dL12-15.5 g/dLLowS
1896-04-14Leukocytes [#/volume] in Blood by Automated count8.610*3/uL4-11 10*3/uLNormalS
1896-04-14Platelets [#/volume] in Blood by Automated count45210*3/uL150-400 10*3/uLHighS
1896-04-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma12U/L7-35 U/LNormalS
1896-04-14Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L10-35 U/LNormalS
1896-04-14Bilirubin.total [Mass/volume] in Serum or Plasma0.4mg/dL0.1-1.2 mg/dLNormalS
1896-04-14Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma74U/L35-104 U/LNormalS
1896-04-14Albumin [Mass/volume] in Serum or Plasma3.3g/dL3.5-5 g/dLLowS
1896-04-14Creatinine [Mass/volume] in Serum or Plasma0.56mg/dL0.5-1 mg/dLNormalS
1896-04-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1891)/1.73 sq M131mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1896-04-14Glucose [Mass/volume] in Serum or Plasma82mg/dL70-99 mg/dLNormalS
1896-04-14Hemoglobin A1c/Hemoglobin.total in Blood5.1%Below 5.7% is normal; 6.5% or more is diabetesNormalS
1896-04-14Visual acuity uncorrected Right eye by ETDRS eye chart85{letters}>=80NormalS
1896-04-14Visual acuity uncorrected Left eye by ETDRS eye chart85{letters}>=80NormalS
1896-04-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]8{score}S
1896-04-14Total score [AUDIT-C]0{score}S
1896-05-01Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS
1896-05-01Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L10-35 U/LNormalS
1896-05-01Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
1896-05-01Visual acuity uncorrected Right eye by ETDRS eye chart85{letters}>=80NormalS
1896-05-01Visual acuity uncorrected Left eye by ETDRS eye chart84{letters}>=80NormalS
1896-06-12Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L7-35 U/LNormalS
1896-06-12Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma25U/L10-35 U/LNormalS
1896-06-12Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
1896-06-12Albumin [Mass/volume] in Serum or Plasma3.8g/dL3.5-5 g/dLNormalS
1896-06-12Hemoglobin [Mass/volume] in Blood12.4g/dL12-15.5 g/dLNormalS
1896-06-12Visual acuity uncorrected Right eye by ETDRS eye chart85{letters}>=80NormalS
1896-06-12Visual acuity uncorrected Left eye by ETDRS eye chart85{letters}>=80NormalS
1896-06-12Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1896-10-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L7-35 U/LNormalS
1896-10-20Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L10-35 U/LNormalS
1896-10-20Albumin [Mass/volume] in Serum or Plasma4.2g/dL3.5-5 g/dLNormalS
1896-10-20Hemoglobin [Mass/volume] in Blood13.2g/dL12-15.5 g/dLNormalS
1896-10-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
1896-08-24Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1896-08-24Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]4{score}S
1896-08-24Total score [AUDIT-C]0{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1896-04-14Body height148cmS
1896-04-14Body weight38.5kgS
1896-04-14Body mass index (BMI) [Ratio]17.6kg/m2S
1896-04-14Systolic blood pressure98mm[Hg]S
1896-04-14Diastolic blood pressure62mm[Hg]S
1896-04-14Heart rate104/minS
1896-04-14Respiratory rate20/minS
1896-04-14Body temperature37.8CelS
1896-04-14Oxygen saturation in Arterial blood by Pulse oximetry96%S
1896-04-17Body height148cmS
1896-04-17Body weight38.4kgS
1896-04-17Body mass index (BMI) [Ratio]17.5kg/m2S
1896-04-17Systolic blood pressure96mm[Hg]S
1896-04-17Diastolic blood pressure60mm[Hg]S
1896-04-17Heart rate100/minS
1896-04-17Respiratory rate20/minS
1896-04-17Body temperature37.6CelS
1896-04-17Oxygen saturation in Arterial blood by Pulse oximetry96%S
1896-05-01Body height148cmS
1896-05-01Body weight39.2kgS
1896-05-01Body mass index (BMI) [Ratio]17.9kg/m2S
1896-05-01Systolic blood pressure100mm[Hg]S
1896-05-01Diastolic blood pressure62mm[Hg]S
1896-05-01Heart rate90/minS
1896-05-01Respiratory rate18/minS
1896-05-01Body temperature37.1CelS
1896-05-01Oxygen saturation in Arterial blood by Pulse oximetry97%S
1896-06-12Body height148cmS
1896-06-12Body weight41kgS
1896-06-12Body mass index (BMI) [Ratio]18.7kg/m2S
1896-06-12Systolic blood pressure102mm[Hg]S
1896-06-12Diastolic blood pressure64mm[Hg]S
1896-06-12Heart rate80/minS
1896-06-12Respiratory rate16/minS
1896-06-12Body temperature36.8CelS
1896-06-12Oxygen saturation in Arterial blood by Pulse oximetry98%S
1896-10-20Body height148cmS
1896-10-20Body weight44kgS
1896-10-20Body mass index (BMI) [Ratio]20.1kg/m2S
1896-10-20Systolic blood pressure106mm[Hg]S
1896-10-20Diastolic blood pressure68mm[Hg]S
1896-10-20Heart rate72/minS
1896-10-20Respiratory rate14/minS
1896-10-20Body temperature36.5CelS
1896-10-20Oxygen saturation in Arterial blood by Pulse oximetry98%S
1896-07-20Body height148cmS
1896-07-20Body weight42kgS
1896-07-20Body mass index (BMI) [Ratio]19.2kg/m2S
1896-07-20Systolic blood pressure104mm[Hg]S
1896-07-20Diastolic blood pressure66mm[Hg]S
1896-07-20Heart rate84/minS
1896-07-20Respiratory rate16/minS
1896-07-20Body temperature37CelS
1896-07-20Oxygen saturation in Arterial blood by Pulse oximetry98%S
1896-08-24Body height148cmS
1896-08-24Body weight42.6kgS
1896-08-24Body mass index (BMI) [Ratio]19.4kg/m2S
1896-08-24Systolic blood pressure104mm[Hg]S
1896-08-24Diastolic blood pressure66mm[Hg]S
1896-08-24Heart rate76/minS
1896-08-24Respiratory rate14/minS
1896-08-24Body temperature36.6CelS
1896-08-24Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
1896-04-14New patient visit for seven weeks of cough, fevers, night sweats and weight loss: chest X-ray, sputum specimens, blood tests, airborne precautions, and a report of suspected tuberculosis to the public health centerfinishedS
1896-04-17Results visit: pulmonary tuberculosis confirmed; infectious diseases consultation and the start of the standard six-month regimenfinishedS
1896-05-01Two-week review on treatment: culture result, liver tests, vision, and release from precautionsfinishedS
1896-06-12End of the eight-week intensive phase: susceptibility results, the two-month sputum culture, and the start of the continuation phasefinishedS
1896-10-20End-of-treatment review after 182 dosesfinishedS
1896-07-20Same-day sick visit for acute cystitis during tuberculosis treatmentfinishedS
1896-08-24Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Diagnosis and safety: chest X-ray; three sputum specimens at least eight hours apart, one early in the morning, for acid-fast smear, Xpert MTB/RIF Ultra, liquid and solid culture and drug susceptibility testing; HIV, hepatitis B and hepatitis C tests and a pregnancy test; blood count, liver and kidney tests, glucose and hemoglobin A1c; visual acuity and color vision before ethambutolcompletedGL-ATS-TBDX-2017, GL-ATS-TB-2016, GL-WHO-TB-2022S
Infectious diseases consultation at the results visit to confirm the diagnosis, choose between the six-month and four-month regimens, set the doses for her weight, and plan monitoring and infection controlcompletedGL-ATS-TB-2016, GL-ATS-TB-2025, GL-CDC-4MO-2022S
Infection control and public health: airborne precautions in the clinic; at home, no visitors, a surgical mask in shared rooms, windows open, and sleeping in her own room until the public health center confirms she is no longer infectious; report of suspected tuberculosis to the public health center the same day and notification at once on diagnosis; a contact investigation of her household and other close contacts led by the public health centercompletedGL-MHLW-TB-NOTIFY, GL-CDC-CONTACT-2005, GL-ATS-TB-2016S
Nutrition, income and writing: two dietitian visits in the first month, three meals and two energy-dense snacks a day with two oral nutrition supplement drinks, and weight at every visit; a medical social worker to apply for public funding of tuberculosis treatment and to review other help with costs; a paced writing plan of short sessions in daylight with rest; PHQ-9 at intake, at two months and at the end of treatmentcompletedGL-ASPEN-MALN-2012, GL-JP-TB-FUNDING, GL-USPSTF-DEP-2023S
Treatment: isoniazid 200 mg, rifampin 450 mg, pyrazinamide 1000 mg and ethambutol 600 mg daily for eight weeks, then isoniazid and rifampin daily for eighteen weeks, with pyridoxine 50 mg, by daily video-observed therapy with the public health center; ethambutol stopped once the isolate is susceptible to isoniazid and rifampin; liver tests at two weeks and monthly in the intensive phase because of her low weight and albumin; visual acuity and color vision monthly while on ethambutol; sputum smear and culture at two weeks and two months; chest X-ray at the end of treatmentcompletedGL-ATS-TB-2016, GL-ATS-TB-2025, GL-WHO-TB-2022, GL-ATS-HEPATOTOX-2006S
Acute cystitis: nitrofurantoin 100 mg twice daily for five days with urine culture; no fluoroquinolone, because these drugs are kept for drug-resistant tuberculosis and can blur the picture of tuberculosis; continue every tuberculosis dose; plenty of fluids; return for fever, flank pain, vomiting or symptoms that are not better in two dayscompletedGL-IDSA-UTI-2010, GL-ATS-TB-2016S
Prevention: cervical cytology now and every three years; Tdap; hepatitis B vaccine in two doses and HPV vaccine in three doses; influenza vaccine in the autumn; folic acid 0.4 mg daily advised; contraception counseling that rifampin makes hormonal pills, patches, rings and implants unreliable, with a copper IUD, injectable progestin or condoms as reliable choices if she needs contraception during treatmentcompletedGL-USPSTF-CERV-2018, GL-CDC-IMZ-2026, GL-CDC-SPR-2024, GL-USPSTF-FOLIC-2023S

Goals

GoalTargetStatusOutcomeProvenance
Complete 182 daily doses within about six and a half months by video-observed therapy1896-10-20completedAll 182 doses completed in 26 weeks: 56 in the intensive phase and 126 in the continuation phase, none missedS
Sputum culture negative at two months1896-10-20completedThe cultures taken at two weeks and at two months both showed no growth after six weeksS
Weight at least 44 kg (BMI about 20) by the end of treatment1896-10-20completed44.0 kg at the end of treatment, from 38.5 kg at intakeS
Keep writing on a paced schedule without losing income during treatment1896-10-20completedPublic funding covered most treatment costs; she kept writing about two hours a day and finished new workS
No drug-induced liver injury or loss of vision during treatment1896-10-20completedLiver tests normal throughout; visual acuity unchangedS

Functional Status

Mental Status